Compare Biocon Ltd with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs LUPIN - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LUPIN BIOCON /
LUPIN
 
P/E (TTM) x 17.4 48.9 35.6% View Chart
P/BV x 2.7 2.5 107.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 BIOCON    LUPIN
EQUITY SHARE DATA
    BIOCON
Mar-18
LUPIN
Mar-19
BIOCON /
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,188986 120.5%   
Low Rs305720 42.3%   
Sales per share (Unadj.) Rs68.7369.5 18.6%  
Earnings per share (Unadj.) Rs7.613.4 56.3%  
Cash flow per share (Unadj.) Rs14.037.4 37.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.3303.7 28.4%  
Shares outstanding (eoy) m600.00452.49 132.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.3 470.4%   
Avg P/E ratio x98.963.6 155.3%  
P/CF ratio (eoy) x53.422.8 234.1%  
Price / Book Value ratio x8.62.8 307.7%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,900386,064 116.0%   
No. of employees `0006.117.7 34.8%   
Total wages/salary Rs m9,31131,513 29.5%   
Avg. sales/employee Rs Th6,705.89,453.8 70.9%   
Avg. wages/employee Rs Th1,514.21,782.0 85.0%   
Avg. net profit/employee Rs Th736.9343.0 214.8%   
INCOME DATA
Net Sales Rs m41,234167,182 24.7%  
Other income Rs m2,0623,640 56.6%   
Total revenues Rs m43,296170,822 25.3%   
Gross profit Rs m8,29128,822 28.8%  
Depreciation Rs m3,85110,850 35.5%   
Interest Rs m6153,078 20.0%   
Profit before tax Rs m5,88718,534 31.8%   
Minority Interest Rs m213-89 -238.5%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1,5699,017 17.4%   
Profit after tax Rs m4,5316,066 74.7%  
Gross profit margin %20.117.2 116.6%  
Effective tax rate %26.748.7 54.8%   
Net profit margin %11.03.6 302.9%  
BALANCE SHEET DATA
Current assets Rs m41,486138,536 29.9%   
Current liabilities Rs m21,41361,299 34.9%   
Net working cap to sales %48.746.2 105.4%  
Current ratio x1.92.3 85.7%  
Inventory Days Days6484 76.3%  
Debtors Days Days94112 83.8%  
Net fixed assets Rs m50,661127,516 39.7%   
Share capital Rs m3,000905 331.5%   
"Free" reserves Rs m48,808136,517 35.8%   
Net worth Rs m51,808137,422 37.7%   
Long term debt Rs m17,89866,417 26.9%   
Total assets Rs m99,897279,494 35.7%  
Interest coverage x10.67.0 150.6%   
Debt to equity ratio x0.30.5 71.5%  
Sales to assets ratio x0.40.6 69.0%   
Return on assets %5.23.3 157.5%  
Return on equity %8.74.4 198.1%  
Return on capital %9.68.9 108.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05859,414 20.3%   
Fx outflow Rs m7,34822,282 33.0%   
Net fx Rs m4,71037,132 12.7%   
CASH FLOW
From Operations Rs m6,62116,660 39.7%  
From Investments Rs m-6,840-32,825 20.8%  
From Financial Activity Rs m-2,3977,441 -32.2%  
Net Cashflow Rs m-2,612-8,724 29.9%  

Share Holding

Indian Promoters % 40.4 46.6 86.7%  
Foreign collaborators % 20.6 0.2 10,300.0%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 31.9 33.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.1 197.0%  
Shareholders   109,995 98,259 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 13, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS